Results 91 to 100 of about 24,787 (310)
Successful Treatment of Severe Adult Linear IgA Dermatosis Using Dupilumab
JEADV Clinical Practice, EarlyView.ABSTRACT Linear IgA dermatosis (LAD) is a rare autoimmune subepidermal bullous dermatosis, characterised by the presence of erythematous vesiculobullous lesions arranged in rosettes or herpetiform clusters. The standard treatment involves the administration of dapsone, followed by sulfasalazine, and general corticosteroid therapy, often in combination ...
Célia Delesalle +7 more
wiley +1 more source
Emerging Topical and Systemic JAK Inhibitors in Dermatology [PDF]
, 2019 Accumulating data on cellular and molecular pathways help to develop novel therapeutic strategies in skin inflammation and autoimmunity. Examples are psoriasis and atopic dermatitis, two clinically and immunologically well-defined disorders.
Ghoreschi, Kamran +2 more
core +1 more source
JEADV Clinical Practice, EarlyView.ABSTRACT Background Atopic dermatitis (AD) is a common inflammatory skin disease. However, limited data exist on its prevalence and incidence in Irish secondary care. Objectives REVEAL AD had two distinct but related objectives: (1) Estimate prevalence of moderate‐to‐severe AD in patients aged 12 years and older presenting to secondary care clinics in ...
Oisín S. Gough +6 more
wiley +1 more source
Consistency of Response to Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis Over 1 Year [PDF]
, 2022 Andrew Blauvelt +5 more
openalex +1 more source
JEADV Clinical Practice, EarlyView.ABSTRACT Artificial Intelligence is rapidly transforming allergology by enhancing diagnosis, risk prediction, automation, patient communication, education, and therapy development. Machine learning approaches, including convolutional neural networks, recurrent architectures, and transformer‐based models, enable analysis of complex datasets from ...
Sebastian Seurig +2 more
wiley +1 more source
Facial erythema after the treatment of dupilumab in SLE patient
Allergy, Asthma & Clinical Immunology, 2020 Background Dupilumab is a receptor antagonist binding to the alpha subunit of the interleukin-4 receptor. Through binding to it, dupilumab inhibits signaling of both IL-4 and IL-13, the representative Th2 biomarkers.
Dong Hyek Jang +5 more
doaj +1 more source
Refractory Eczema as a Presenting Feature of Common Variable Immunodeficiency
JEADV Clinical Practice, EarlyView.ABSTRACT Common variable immunodeficiency (CVID) is the most prevalent symptomatic inborn error of immunity (IEI) in adults. It presents with recurrent infections and non‐infectious complications, including autoimmunity, lymphoproliferation and dermatitis.
Mercedes Sanchez‐Diaz +2 more
wiley +1 more source
Cytokine and Lipid Mediator Regulation of Group 2 Innate Lymphoid Cells (ILC2s) in Human Allergic Airway Disease. [PDF]
, 2017 The recent discovery of group 2 innate lymphoid cells (ILC2s) has caused a paradigm shift in the understanding of allergic airway disease pathogenesis.
Cavagnero, Kellen, Doherty, Taylor A
core +2 more sources
Use patterns of systemic immunomodulators in the United States before and after dupilumab approval in adults with atopic dermatitis [PDF]
, 2022 Priyanka Anand +3 more
openalex +1 more source
HPV‐6 Positive Eruptive Verruca Vulgaris After Upadacitinib Initiation for Severe Atopic Dermatitis
JEADV Clinical Practice, EarlyView.ABSTRACT Oral JAK‐1 inhibitors for atopic dermatitis (AD) are associated with an increased risk of cutaneous viral infections, particularly herpes zoster. Emerging case reports further suggest a link to eruptive human papillomavirus (HPV) disease. A 23‐year‐old transgender man (female‐to‐male) with severe AD developed a rapidly disseminating eruption ...
Mohammed Shanshal +2 more
wiley +1 more source